Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

Abemaciclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6 that inhibits the transition from the G1 to the S phase of the cell cycle by blocking downstream CDK4/6-mediated phosphorylation of Rb. The effects of abemaciclib alone or combined with the third-generation epidermal growth factor...

Full description

Bibliographic Details
Main Authors: Silvia La Monica, Claudia Fumarola, Daniele Cretella, Mara Bonelli, Roberta Minari, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Francesco Volta, Maicol Mancini, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
non-small cell lung cancer
osimertinib
resistance
epidermal growth factor receptor
abemaciclib
CDK4/6 inhibitors
Online Access:https://www.mdpi.com/2072-6694/13/1/6

Internet

https://www.mdpi.com/2072-6694/13/1/6

Similar Items